Registration No. 33-20065
As filed with the United States Securities and Exchange Commission on March 26, 2008
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OF 1933
LIFECORE BIOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
     
Minnesota   41-0948334
(State or other jurisdiction   (I.R.S. Employer
of incorporation or   Identification No.)
organization)    
3515 Lyman Boulevard
Chaska, Minnesota 55318
(Address of Principal Executive Offices)
LIFECORE BIOMEDICAL, INC. 1987 STOCK OPTION PLAN
(Full title of the plan)
Dennis J. Allingham
Chief Executive Officer
Lifecore Biomedical, Inc.
3515 Lyman Boulevard
Chaska, Minnesota 55318
(952) 368-4300
(Name and address of agent for service)

Copy to:
Robert A. Rosenbaum
Dorsey & Whitney LLP
50 South Sixth Street, Suite 1500
Minneapolis, Minnesota 55402
(612) 340-2600
 
     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
             
Large accelerated filer o     Accelerated filer þ     Non-accelerated filer   o
(Do not check if a smaller reporting company) 		  Smaller Reporting Company o  
 
 

 

 

TERMINATION OF REGISTRATION OF SECURITIES
     This Post-Effective Amendment No. 1 relates to the Registration Statement on Form S-8 (Registration No. 33-20065) (the “ Registration Statement ”) of Lifecore Biomedical, Inc. (the " Company ”), which was filed with the U.S. Securities and Exchange Commission on February 18, 1988. The Registration Statement registered 300,000 shares of the Company’s common stock, par value $.01 per share, (the “ Common Stock ”) pursuant to the Company’s 1987 Stock Option Plan (the “ Plan ”).
     On March 26, 2008 (the “ Closing Date ”), pursuant to the terms of that certain Agreement and Plan of Merger, dated as of January 15, 2008, by and among SBT Holdings Inc., a Delaware corporation (the “ Parent ”), SBT Acquisition Inc., a Minnesota corporation and wholly owned subsidiary of the Parent (the “ Purchaser ”), and the Company, the Purchaser was merged with and into the Company with the Company continuing as the surviving corporation (the “ Merger ”). As a result of the Merger, the Common Stock is held of record by fewer than 300 persons. Accordingly, the Company intends to file a Certification and Notice of Termination of Registration on Form 15 with the Securities and Exchange Commission with respect to its Common Stock.
     As a result of the Merger, no additional shares of Common Stock will be issued under the Plan. The Company is filing this Post-Effective Amendment No. 1 to remove and withdraw from registration all shares of Common Stock and any additional securities registered pursuant to this Registration Statement that remain unissued.

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chaska, State of Minnesota, on the 26 th day of March, 2008.
         
  LIFECORE BIOMEDICAL, INC.
  		 
  By:   /s/ Dennis J. Allingham    
    Dennis J. Allingham   
    President and Chief Executive Officer   
 
     Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities indicated on the 26 th day of March, 2008.
     
Signature   Title
 
   
/s/ Dennis J. Allingham
 
Dennis J. Allingham
  President, Chief Executive Officer and Director
(principal executive officer)
 
   
/s/ David M. Noel
 
David M. Noel
  Vice President of Finance and Chief Financial Officer (principal financial and accounting officer)
 
   
 
   
*
 
Martin J. Emerson
  Director 
 
   
*
 
Thomas H. Garrett
  Director 
 
   
*
 
Luther T. Griffith
  Director 
 
   
*
 
Richard W. Perkins
  Director 
 
   
*
 
John E. Runnells, III
  Lead Director 
         
* By
  /s/ Dennis J. Allingham    
 
       
 
  Dennis J. Allingham    
    Attorney-in-Fact, pursuant to Power of Attorney filed herewith

 

 

INDEX TO EXHIBITS
     
Exhibit No.
   
 
Exhibit 24  
Power of Attorney

 

Lifecore Biomedical (MM) (NASDAQ:LCBM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Lifecore Biomedical (MM) Charts.
Lifecore Biomedical (MM) (NASDAQ:LCBM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Lifecore Biomedical (MM) Charts.